Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARM011 in Relapsed/Refractory B-Cell ALL
NCT07066397Phase 1Recruiting
- Sponsor
- TriArm Therapeutics
- Start
- Jul 2025
- Primary completion
- Apr 2028
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label trial of GC007F in acute lymphoblastic leukemia (ALL), sponsored by TriArm Therapeutics. Primary endpoint: Incidence of adverse events at 24 months. Started Jul 2025; status: recruiting.
02
Drugs
GC007F
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT07066397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07066397.